Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab
Circulation: Cardiovascular Imaging · 2024
DOI: 10.1161/circimaging.124.016683 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Circulation: Cardiovascular Imaging, 2024. Verfasst von Konstantinos C Koskinas und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Bern University Hospital, Inselspital (K.C.K., J.H., Y.U., T.O., H.S., R.K., F.P., M.A., J. Lanz, S.W., L.R.), University o…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Biomarkers, Coronary Artery Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy. METHODS: In the PACMAN-AMI trial (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction), 300 patients with acute myocardial infarction were randomized to receive biweekly alirocumab 150 mg or placebo in addition to high-intensity statins. Patients underwent serial 2-vessel intravascular ultrasound, optical coherence tomography, and near-infrared spectroscopy in the non–infarct-related arteries at baseline and after 52 weeks. The main end points were percent atheroma volume by intravascular ultrasound, minimum fibrous cap thickness by optical coherence tomography, and maximum lipid core burden index within 4 mm (maxLCBI 4mm ) by near-infrared spectroscopy. RESULTS: A total of 265 patients had serial intravascular ultrasound data (mean age, 58±9 years; 16% women). Alirocumab resulted in greater reductions in percent atheroma volume and maxLCBI 4mm , as well as a greater increase in minimum fibrous cap thickness, compared with placebo. In the alirocumab group, the reduction in maxLCBI 4mm was smaller in patients with higher baseline Lp(a), defined by the highest quartile (Q4, ≥98 nmol/L; n=30), than in those with lower baseline Lp(a) (Q1–Q3,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Bern University Hospital, Inselspital (K.C.K., J.H., Y.U., T.O., H.S., R.K., F.P., M.A., J. Lanz, S.W., L.R.), University of Bern, Switzerland.
- Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (J. Lonborg, T.E.).
- Department of Cardiology, University Hospital Basel, Switzerland (C.K.).
- Department of Cardiology, Radboud UMC, Nijmegen, the Netherlands (R.-J.v.G.).
- Department of Cardiology, Medical University of Vienna, Austria (A.S.O., M.M.; I.M.L.).
- Institute of Pharmacology, Bern University Hospital (D.S.), University of Bern, Switzerland.
ORCID-Profile: Konstantinos C Koskinas, Jonas Häner, Yasushi Ueki, Tatsuhiko Otsuka, Hiroki Shibutani, Ryota Kakizaki, Robert-Jan van Geuns, Anna S Ondracek, Fabien Praz, Jonas Lanz, Joost Daemen, Dik Heg, Manuel Mayr, François Mach, Stephan Windecker, Thomas Engstrøm, Irene M Lang, Arnold von Eckardstein, Lorenz Räber
Zitieren
APA
Koskinas, K. C., Häner, J., Ueki, Y., Otsuka, T., Lonborg, J., Shibutani, H., Kakizaki, R., Kaiser, C., van Geuns, R. J., Ondracek, A. S., Praz, F., Ambühl, M., Spirk, D., Lanz, J., Daemen, J., Heg, D., Mayr, M., Mach, F., Windecker, S., …, & Räber, L. (2024). Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab. Circulation: Cardiovascular Imaging. https://doi.org/10.1161/circimaging.124.016683
Vancouver
Koskinas KC, Häner J, Ueki Y, Otsuka T, Lonborg J, Shibutani H, et al. Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab. Circulation: Cardiovascular Imaging. 2024. doi:10.1161/circimaging.124.016683
BibTeX
@article{Koskinas2024,
author = {Koskinas, Konstantinos C and Häner, Jonas and Ueki, Yasushi and Otsuka, Tatsuhiko and Lonborg, Jacob and Shibutani, Hiroki and Kakizaki, Ryota and Kaiser, Christoph and van Geuns, Robert-Jan and Ondracek, Anna S and Praz, Fabien and Ambühl, Maria and Spirk, David and Lanz, Jonas and Daemen, Joost and Heg, Dik and Mayr, Manuel and Mach, François and Windecker, Stephan and Engstrøm, Thomas and Lang, Irene M and von Eckardstein, Arnold and Losdat, Sylvain and Räber, Lorenz},
title = {Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab},
journal = {Circulation: Cardiovascular Imaging},
year = {2024},
doi = {10.1161/circimaging.124.016683}
}
EUVIMED